All In MedTech

Device Trial Radar · NCT05409989

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

Sep 20, 2022

Primary completion

Apr 2027

Study completion May 2030

Sponsor

Lead sponsor
Microvention-Terumo, Inc.Public (4543.T)
Sponsor type
Industry
First posted
Jun 8, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

Conditions

  • Intracranial Aneurysm

Interventions

  • FRED™ X™Device

    The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint Part 1: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure.Time frame: 30-days
  2. Primary Safety Endpoint Part 2: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure.Time frame: 12 months
  3. Primary Effectiveness Endpoint: The percent of subjects with (1) complete (100%) occlusion of the target aneurysm and ≤50% stenosis of the parent artery at the target IA, and (2) in whom an alternative treatment of the target IA had not been performed.Time frame: 12 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Healthcare Systems

    Hollywood, Florida

  • Orlando Health

    Orlando, Florida

  • Queen's Medical Center

    Honolulu, Hawaii

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.